Patrick J. Quinn

197 Wellington Street
Perth, WA 6000, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Cost-Effectiveness of Oral Immunotherapy Treatments vs No Treatment for Peanut Allergy in Children.

Cost-Effectiveness of Oral Immunotherapy Treatments vs No Treatment for Peanut Allergy in Children.

Journal: JAMA network open

Published: March 20, 2026

Three-Year Post-Treatment Outcomes Following Cessation of Peanut Oral Immunotherapy: Comparisons by Clinical Allergy Status and Treatment Group.

Three-Year Post-Treatment Outcomes Following Cessation of Peanut Oral Immunotherapy: Comparisons by Clinical Allergy Status and Treatment Group.

Journal: Allergy

Published: November 21, 2025

Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program.

Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: July 20, 2025

Sex assigned at birth may modify health-related quality of life in children treated with peanut oral immunotherapy.

Sex assigned at birth may modify health-related quality of life in children treated with peanut oral immunotherapy.

Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology

Published: March 18, 2025

Characterisation of a Leaky Splice-Site Mutation Associated with Phenotypic Diversity in Two Unrelated Patients with ARPC1B Deficiency.

Characterisation of a Leaky Splice-Site Mutation Associated with Phenotypic Diversity in Two Unrelated Patients with ARPC1B Deficiency.

Journal: Journal of clinical immunology

Published: December 23, 2024

Allergen-Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1-10 Years.

Allergen-Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1-10 Years.

Journal: Allergy

Published: August 15, 2024

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE.

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE.

Journal: The journal of allergy and clinical immunology. In practice

Published: August 07, 2024

Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) study.

Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) study.

Journal: Allergy

Published: December 19, 2023

Interaction Between Baseline Participant Factors and Treatment Effects Following Peanut Oral Immunotherapy.

Interaction Between Baseline Participant Factors and Treatment Effects Following Peanut Oral Immunotherapy.

Journal: The journal of allergy and clinical immunology. In practice

Published: September 10, 2023

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.

Journal: The New England journal of medicine

Published: May 10, 2023

Association of Reaction Symptoms and Eliciting Dose With Health-Related Quality of Life in Children With Peanut Allergy.

Association of Reaction Symptoms and Eliciting Dose With Health-Related Quality of Life in Children With Peanut Allergy.

Journal: The journal of allergy and clinical immunology. In practice

Published: March 14, 2023

PrEggNut Study: protocol for a randomised controlled trial investigating the effect of a maternal diet rich in eggs and peanuts from <23 weeks' gestation during pregnancy to 4 months' lactation on infant IgE-mediated egg and peanut allergy outcomes.

PrEggNut Study: protocol for a randomised controlled trial investigating the effect of a maternal diet rich in eggs and peanuts from <23 weeks' gestation during pregnancy to 4 months' lactation on infant IgE-mediated egg and peanut allergy outcomes.

Journal: BMJ open

Published: June 13, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026